Skip to main content
Top

Cancer Immunology, Immunotherapy

Issue 8/2013

Content (15 Articles)

Original Article

Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients

Michael A. Morse, Arvind Chaudhry, Elizabeth S. Gabitzsch, Amy C. Hobeika, Takuya Osada, Timothy M. Clay, Andrea Amalfitano, Bruce K. Burnett, Gayathri R. Devi, David S. Hsu, Younong Xu, Stephanie Balcaitis, Rajesh Dua, Susan Nguyen, Joseph P. Balint Jr., Frank R. Jones, H. Kim Lyerly

Original Article

Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the Hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival

Richard K. Yang, Nicholas A. Kalogriopoulos, Alexander L. Rakhmilevich, Erik A. Ranheim, Songwon Seo, KyungMann Kim, Kory L. Alderson, Jacek Gan, Ralph A. Reisfeld, Stephen D. Gillies, Jacquelyn A. Hank, Paul M. Sondel

Original article

The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells

Stefanie Trojandt, Diana Knies, Stefanie Pektor, Sandra Ritz, Volker Mailänder, Stephan Grabbe, Angelika B. Reske-Kunz, Matthias Bros

Original Article

A case of spontaneous systemic immunity to melanoma associated with cure after amputation for extensive regional recurrence

Joshua M. Judge, Louis B. Brill II, Kelly T. Smith, Donna H. Deacon, James W. Patterson, William W. Grosh, Achim A. Jungbluth, Sacha Gnjatic, Craig L. Slingluff Jr.

Original Article

Gamma delta T cells are activated by polysaccharide K (PSK) and contribute to the anti-tumor effect of PSK

Carol Inatsuka, Yi Yang, Ekram Gad, Lauren Rastetter, Mary L. Disis, Hailing Lu

Original Article

TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells

Ryan M. Stephenson, Chwee Ming Lim, Maura Matthews, Gregory Dietsch, Robert Hershberg, Robert L. Ferris

Original Article

A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells

Dhifaf Sarhan, Erik Wennerberg, Padraig D’Arcy, Deepthy Gurajada, Stig Linder, Andreas Lundqvist

Original Article

Evaluating combinations of costimulatory antibody–ligand fusion proteins for targeted cancer immunotherapy

Nora Hornig, Katharina Reinhardt, Vanessa Kermer, Roland E. Kontermann, Dafne Müller

Original Article

Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients

Willemijn Hobo, Leonie Strobbe, Frans Maas, Hanny Fredrix, Annelies Greupink-Draaisma, Ben Esendam, Theo de Witte, Frank Preijers, Henriëtte Levenga, Bas van Rees, Reinier Raymakers, Nicolaas Schaap, Harry Dolstra

Original Article

Avidity of onconeural antibodies is of clinical relevance

Cecilie Totland, Ming Ying, Mette Haugen, Kibret Mazengia, Anette Storstein, Jan Aarseth, Aurora Martinez, Christian Vedeler

Original Article

Intravenous infusion of phage-displayed antibody library in human cancer patients: enrichment and cancer-specificity of tumor-homing phage-antibodies

Girja S. Shukla, David N. Krag, Elena N. Peletskaya, Stephanie C. Pero, Yu-Jing Sun, Chelsea L. Carman, Laurence E. McCahill, Thomas A. Roland

Open Access Original Article

Ficolin-2 and ficolin-3 in women with malignant and benign ovarian tumours

Agnieszka Szala, Sambor Sawicki, Anna St. Swierzko, Janusz Szemraj, Marcin Sniadecki, Mateusz Michalski, Andrzej Kaluzynski, Jolanta Lukasiewicz, Anna Maciejewska, Dariusz Wydra, David C. Kilpatrick, Misao Matsushita, Maciej Cedzynski

Original Article

Increase in CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis

Fumitaka Arihara, Eishiro Mizukoshi, Masaaki Kitahara, Yoshiko Takata, Kuniaki Arai, Tatsuya Yamashita, Yasunari Nakamoto, Shuichi Kaneko

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine